Indication
for the prophylaxis of migraine in adults who have at least 4 migraine days per month

Medicine details

Medicine name:
erenumab (Aimovig)
SMC ID:
SMC2134
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Central nervous system
Submission type
Full submission
Status
Advice due date:
08 April 2019
SMC meeting date:
05 March 2019
Patient group submission deadline:
04 February 2019